Oct 2026· Proceedings of the OJSS Virtual Research Conference 2026· 0 citations
TL;DR
A convergence model is established, where GBA1 and LRRK2 mutations disrupt different checkpoints of the PINK1/Parkin mitophagy axis, but converge on the common collapse of mitochondrial quality control that creates both genotype-specific and shared therapeutic targets in PD.
Abstract
Parkinson’s Disease (PD) is a complex progressive neurodegenerative disease with certain cases exhibiting non-idiopathic forms. Understanding this allows for a better understanding about the disease and treatment options. The 2 main genetic forms of PD are mutations in the Glucosylceramidase Beta 1 (GBA1) and Leucine-Rich Repeat Kinase 2 (LRRK2) genes. GBA1 and LRRK2 gene mutations disrupt mitophagy through distinct mechanisms that converge on PINK1/Parkin-linked mitochondrial quality control in PD. GBA1 mutations impair lysosomal enzyme glucocerebrosidase (GCase), causing toxic substance accumulation and an aggressive phenotype of early motor declining and severe non-motor symptoms. Pathogenic LRRK2 mutations induce a toxic gain of function by hyperactivating kinase activity, significantly increasing phosphorylation of downstream Rab GTPases and disrupting vital endolysosomal trafficking. This impairs mitophagy and clearance of misfolded proteins, ultimately driving neurodegeneration of dopaminergic neurons. While standard scientific literature traditionally examines these genetic pathways in isolation, they can synergistically disrupt mitophagy and lysosomal pathways causing PD. A joint review is also critical especially as dual-inhibitor clinical trials emerge and multi-mutation carriers present uniquely altered phenotypes. This review establishes a convergence model, where GBA1 and LRRK2 mutations disrupt different checkpoints of the PINK1/Parkin mitophagy axis, but converge on the common collapse of mitochondrial quality control that creates both genotype-specific and shared therapeutic targets.
Hexanucleotide repeat expansions in C9orf72, the most common genetic cause of Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), drive neurodegeneration through both loss of gene function and toxic gain-of-function mechanisms, including transcription of repeat RNA and repeat-associated non-AUG (RAN)...
Paulien H. Smeele, V. Ferrari, Giorgia Spina et al.· bioRxiv· 0 citations
A systematic review systematically delineates the molecular framework of the Parkin‑CMA‑NLRP3‑PANoptosis signaling axis and summarizes translational progress of small‑molecule compounds and gene therapies targeting individual components within this cascade.
Xing-Hua Tian, Biao Zhang, Yu Wang et al.· Progress in neurobiology· 0 citations
Mutations in the LRRK2 gene are a major genetic cause of Parkinson’s disease (PD) and induce hyperphosphorylation of RAB GTPases through increased LRRK2 kinase activity. The phosphatase PPM1H counteracts this activity by selectively dephosphorylating LRRK2-phosphorylated RAB proteins. Here, we used primary PPM1H knocko...
L. Evers, Jessica M. Grein, C. A. Boecker· Molecular Brain· 0 citations
It is found that PD is a biologically and clinically heterogeneous disease that requires biomarker-directed and genotype-stratified therapeutic development and major translational issues are critically evaluated, including challenges related to blood-brain barrier penetration, target specificity, and long-term safety o...
Abid Khan, T. Jawaid, Z. Urrehman et al.· Experimental Neurology· 0 citations
It is found that Parkin loss also rewires the genetic dependencies that govern neuronal survival, which changes which genes neurons require to survive, so phenotypes read as deficits may instead mark altered requirements, and genotype may determine whether an intervention helps or harms.
Shi-Jie Wang, Daniel R. Gulbranson, Beatrice Costa et al.· bioRxiv· 0 citations
A complex interplay between genes and environmental factors is recognized to contribute to dopaminergic neuron death in Parkinson’s disease (PD). Within the known genes associated with PD, there is Leucine-Rich Repeat Kinase (LRRK2), known as one of the most frequent causes of PD, of either familial or sporadic nature....
B. Marchetti, M. F. Serapide· Antioxidants· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.